It can therefore be used locally in clinical trials to identify the HCV subtype and stratify the patients at inclusion, as well as to interpret efficacy and resistance data.
As a result of these findings, correct identification of HCV subtypes 1a and 1b is crucial in clinical trials assessing new HCV drugs in order to correctly stratify and interpret efficacy and resistance data.
However, participants expressed confusion or uncertainty in knowing how to interpret efficacy rates and their impact on risk reduction in this particular context.
The SAMS intervention and trial design address weaknesses of previous research by recruitment from a well-characterised population, definition of a feasible theory based intervention to support medication taking and careful measurement to estimate and interpret efficacy.
The trial addresses important limitations in the literature by recruitment from a well-characterised population, definition of a feasible intervention to support medication taking, and careful measurement to estimate and interpret efficacy.
Despite the compilation of an evidence-base in primary care over approximately 25 years, there remains a lack of clarity about the contents of brief interventions 72 and the extent to which existing trials can be interpreted as efficacy or effectiveness studies with important implications for the generalizability of these data 60, 70, 73.
Detailed information on the drug exposure in BLT mice will be important for interpreting the efficacy results in this model and for comparison with efficacy data from human trials when these become available in the near future.
Here, we propose an integrated computational predictive model to interpret the efficacy of drug delivery in the aforementioned process.
Rather, we interpret the efficacy of z-score for reverse-engineering these networks as a strong indication that an algorithm must begin with exploratory data analysis.
This is crucial in interpreting the efficacy of APRV or any partial ventilatory support modality.
